RAD21

Across TCGA pan-cancer cohorts, RAD21 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAD21 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RAD21 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD21 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

BLCA, UCEC, and CHOL are the cancer types where RAD21 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.916	0.493	.004	19	view →
UCEC	DFS	Median	All	0.911	0.620	.016	8	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
LUAD	OS	Median	All	0.335	0.700	.032	3	view →
COAD	DFS	Median	II,III,IV	0.155	0.556	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAD21–BLCA (DFS)

Open the BLCA breakdown →